TriangleNCT04325828 · OUTCOME
Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 13 months
What was measured
Overall survival (OS) was defined as the time from the date of the initial dose of study intervention to the date of the participant's death.
Analysis population: Treated analysis set included all participants who received at least 1 dose of study intervention.
Groups in this outcome
Apalutamide + Goserelin
Participants with androgen receptor (AR) expressing locally advanced or recurrent/metastatic salivary gland carcinoma (SGC) received apalutamide 240 milligrams (mg) (4\*60 mg tablets) orally once daily with or without food in combination with stable regimen of goserelin 3.6 mg administered subcutaneously once per cycle (each cycle is of 28 days) as a gonadotropin-releasing hormone (GnRH) agonist, until disease progression, unacceptable toxicity, death, or end of the study.
| Group | Source count |
|---|---|
| Apalutamide + Goserelin | 31 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Apalutamide + Goserelin | NA | Not reported | NA | NA | The median and 95% confidence interval were not estimable due to very less number of participants with events. |
Complete source fields
- classes
- categories
- measurements
- comment
- The median and 95% confidence interval were not estimable due to very less number of participants with events.
- group Id
- OG000
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 31
- units
- Participants
- description
- Overall survival (OS) was defined as the time from the date of the initial dose of study intervention to the date of the participant's death.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants with androgen receptor (AR) expressing locally advanced or recurrent/metastatic salivary gland carcinoma (SGC) received apalutamide 240 milligrams (mg) (4\*60 mg tablets) orally once daily with or without food in combination with stable regimen of goserelin 3.6 mg administered subcutaneously once per cycle (each cycle is of 28 days) as a gonadotropin-releasing hormone (GnRH) agonist, until disease progression, unacceptable toxicity, death, or end of the study.
- id
- OG000
- title
- Apalutamide + Goserelin
- param Type
- MEDIAN
- population Description
- Treated analysis set included all participants who received at least 1 dose of study intervention.
- reporting Status
- POSTED
- time Frame
- Up to 13 months
- title
- Overall Survival (OS)
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice